Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, announced financial results for the year ended December 31, 2013, and provided an update on its clinical trials of ThermoDox®, Celsion’s proprietary heat-activated liposomal encapsulation of doxorubicin. Thermo Dox is being evaluated in a Phase III clinical trial for primary liver cancer and a Phase II clinical trial for recurrent chest wall breast cancer. Celsion Corporation (NASDAQ:CLSN) shares after opening at $3.34 moved to $3.37 on last trade day and at the end of the day closed at $3,24. Company price to sales ratio in past twelve months was calculated as 139.48 and price to cash ratio as 1.23. Celsion Corporation (NASDAQ:CLSN) showed a negative weekly performance of -3.86%.
Acura Pharmaceuticals, Inc. (ACUR) was a big mover last session, as the company saw its shares rise nearly 8% on the day. This rally higher can be attributable to solid volume with far more shares changing hands than in a normal session. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) shares fell -9.15% in last trading session and ended the day on $1.20. ACUR return on equity ratio is recorded as -67.80% and its return on assets is -57.30%. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) yearly performance is -38.28%.
Spherix Inc (NASDAQ:SPEX) has since lost some ground on the stock market, largely due to a dud volume-based transactions at the end of trading session. The company has reported lesser on the stock prices by 12.45% , closing at $3.00 per share. The volumes trading were at 1.31 million shares. Spherix Inc (NASDAQ:SPEX) shares moved down -12.09% in last trading session and was closed at $2.40, while trading in range of $ 2.31 – 2.78. Spherix Inc (NASDAQ:SPEX) year to date (YTD) performance is -70.22%.
AVEO Pharmaceuticals (NASDAQ: AVEO) shares fell 0.70% to touch a new 52-week low of $1.42. AVEO’s trailing-twelve-month ROE is -113.3. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) weekly performance is -8.67%. On last trading day company shares ended up $1.37. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) distance from 50-day simple moving average (SMA50) is -21.52%. Analysts mean target price for the company is $2.50.